CIBBIM - Nanomedicine

Functional Validation & Preclinical Research (FVPR)

Ibane Abasolo Olaortua

Technicians
Yolanda Fernández Amurgo, Sandra Mancilla Zamora, Laura Barberà Ferrando, Laia Foradad Felip, Natalia García Aranda

 

SUMMARY

The Area of Functional Validation and Preclinical Research (FVPR), is part of the CIBBIM-Nanomedicine research center, and aims to provide the industry and other research groups with an optimum technical platform for testing new biomedical applications based on the nanotechnology from compounds for the treatment of specific diseases to new applications in diagnosis and imaging.

Likewise, the efficacy and toxicity of the therapeutic nanoconjugates developed at CIBBIM-Nanomedicine in collaboration with other research groups and companies are being currently evaluated, with the objective of favouring the entry of those compounds into clinical trials.

The area is formed by two technological platforms, the In vitro Experimental Platform and  the In vivo Experimental Platform. Both platforms are partially financed by the CIBER-BBN (Biomedical Research Networking Center in Biomaterial, Bioingineering and Nanomedicine) and belong to the research infrastructure of CIBER-BBN. The Area of Functional Validation and Preclinical Studies also takes part in the Nanotoxicology Unit of CIBER-BBN, a platform shared with the Institut de Recerca del Hospital de la Santa Creu i Sant Pau.

During 2014 FVPR has provided services to 10 different groups at our institution, 1 group at VHIO and researches at Universitat Autònoma de Barcelona (UAB), Universidad del País Vasco-Euskal Herriko Univertsitatea (UPV-EHU), Universidad Miguel Hernández and University of Coimbra (Portugal). In addition, FVPR has also worked for Nanotherapix SL (a Grifols company) in 6 different research contracts.

PUBLICATIONS

Total 6.
Impact Factor 29.494
Average I.F. 4.916

  • Mateo F, Meca-Cortés O, Celià-Terrassa T, Fernández Y, Abasolo I, Sánchez-Cid L, Bermudo R, Sagasta A, Rodríguez-Carunchio L, Pons M, Cánovas V, Marín-Aguilera M, Mengual L, Alcaraz A, Schwartz S Jr, Mellado B, Aguilera KY, Brekken R, Fernández PL, Paciucci R, Thomson TM. SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. Mol Cancer. 2014 Oct 21;13:237.
  • Pesarrodona M., Ferrer-Miralles N., Unzueta U., Gener P., Tatkiewivcs T, Abasolo I., Ratera I., Veciana J, Schwartz S. Jr., Villaverde A., Vazquez E. Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles. Int J Pharm. In Press. Available online 11 July 2014. DOI: 10.1016/j.ijpharm.2014.07.016. IF: 3.458
  • Candiota A.P., Acosta M., Simões R.V., Delgado-Goñi T., Lope-Piedrafita S., Irure A., Marradi M., Bomati-Miguel O., Miguel-Sancho N., Abasolo I., Schwartz S. Jr, Santamaria J., Penadés S., Arús C. A new ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study. J Nanobiotechnology. 2014 Apr 5;12(1):12.
  • Alaña L., Sesé M., Cánovas V., Punyal Y., Faoro C., Fernández Y., Abasolo I., Vargas G., de Torres I, Marqués N., Ruiz C., Bermudo R., Espinosa L., Bigas A., Ramón y Cajal S., Fernández P.L., Serras F., Corominas M.,Thomson T.M., Paciucci R. Prostate Tumor OVerexpressed 1 (PTOV1) is a novel negative regulator of Notch down-regulates HES1 and HEY1 notch targets genes and promotesprostate cancer progression. Mol Cancer 2014 Mar 31;13(1):74.
  • Bomati-Miguel O., Miguel-Sancho N, Abasolo I., Candiota A.P., Roca A.G., Acosta M., Schwartz S. Jr., Arus C., Marquina C., Martinez G. and Santamaria J. Ex vivo assessment of polyol coated-iron oxide nanoparticles for MRI diagnosis applications: toxicological and MRI contrast enhancement effects. J Nanoparticle Res (IF = 2.175). 2014, 16(3): 2292-7. http://dx.doi.org/10.1007/s11051-014-2292-7

MAIN RESEARCH PROJECTS

During 2014 FVPR has provided services to 10 different groups at our institution, 1 group at VHIO and researches at Universitat Autònoma de Barcelona (UAB), Universidad del País Vasco-Euskal Herriko Univertsitatea (UPV-EHU), Universidad Miguel Hernández and University of Coimbra (Portugal). In addition, FVPR has also worked for Nanotherapix SL (a Grifols company) in 6 different research contracts.

In collaborative research, FVPR has participated in 4 funded projects during 2014, two of at VHIR and two addiontal ones through our participation at CIBER-BBN
PENTRI: Personalized nanomedicine for triple negative breast cancer (IP. Ibane Abasolo). Funded by Marató Tv3
LIPOCELL: Functionalized nanoliposomes for the development of therapies for intracellular-based diseases. Application to Fabry disease and homozygous familial hypercholesterolemia (IP. Simó Schwartz). Funded by CIBER-BBN’s Technology Transfer program and by Praxis Biopharmaceuticals
TERARMET: Desarrollo de terapias para el tratamiento de enfermedades raras metabólicas congénitas (IP. Ibane Abasolo). Funded by
RETOS program.